201 related articles for article (PubMed ID: 26178007)
1. Changing face of care for patients with moderate to severe inflammatory bowel disease: the role of specialist nurses in the governance of anti-TNF prescribing.
Connell WR; Samyue T; Gibson PR; Lachal S; Moore GT; Macrae FA; Van Langenberg DR
Intern Med J; 2015 Nov; 45(11):1161-6. PubMed ID: 26178007
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of a Comprehensive Specialist Inflammatory Bowel Disease Nursing Service.
Yu N; Wu K; Samyue T; Fry S; Stanley A; Ross A; Malcolm R; Connell W; Wright E; Ding NS; Niewiadomski O; Lust M; Schulberg J; Flanagan E; Kamm MA; Basnayake C
Inflamm Bowel Dis; 2024 Jun; 30(6):960-969. PubMed ID: 37643766
[TBL] [Abstract][Full Text] [Related]
3. The impacts of an inflammatory bowel disease nurse specialist on the quality of care and costs in Finland.
Molander P; Jussila A; Toivonen T; Mäkkeli P; Alho A; Kolho KL
Scand J Gastroenterol; 2018 Dec; 53(12):1463-1468. PubMed ID: 30600722
[TBL] [Abstract][Full Text] [Related]
4. The safety and efficacy of antitumour necrosis factor-alpha therapy for inflammatory bowel disease in patients post liver transplantation: a case series.
Sandhu A; Alameel T; Dale CH; Levstik M; Chande N
Aliment Pharmacol Ther; 2012 Jul; 36(2):159-65. PubMed ID: 22616981
[TBL] [Abstract][Full Text] [Related]
5. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.
Gao X; Wendling D; Botteman MF; Carter JA; Rao S; Cifaldi M
J Med Econ; 2012; 15(6):1054-63. PubMed ID: 22563743
[TBL] [Abstract][Full Text] [Related]
6. The effect of an inflammatory bowel disease nurse position on service delivery.
Leach P; De Silva M; Mountifield R; Edwards S; Chitti L; Fraser RJ; Bampton P
J Crohns Colitis; 2014 May; 8(5):370-4. PubMed ID: 24161810
[TBL] [Abstract][Full Text] [Related]
7. Long-term evolution of direct healthcare costs for inflammatory bowel diseases: a population-based study (2006-2015).
Kim JW; Lee CK; Lee JK; Jeong SJ; Oh SJ; Moon JR; Kim HS; Kim HJ
Scand J Gastroenterol; 2019 Apr; 54(4):419-426. PubMed ID: 30905222
[No Abstract] [Full Text] [Related]
8. Sustained improvement in health-related quality of life measures in patients with inflammatory bowel disease receiving prolonged anti-tumor necrosis factor therapy.
Sherman M; Tsynman DN; Kim A; Arora J; Pietras T; Messing S; St Hilaire L; Yoon S; Decross A; Shah A; Saubermann L
J Dig Dis; 2014 Apr; 15(4):174-9. PubMed ID: 24373601
[TBL] [Abstract][Full Text] [Related]
9. Public versus Private Drug Insurance and Outcomes of Patients Requiring Biologic Therapies for Inflammatory Bowel Disease.
Rumman A; Candia R; Sam JJ; Croitoru K; Silverberg MS; Steinhart AH; Nguyen GC
Can J Gastroenterol Hepatol; 2017; 2017():7365937. PubMed ID: 28239601
[No Abstract] [Full Text] [Related]
10. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature.
Cullen G; Kroshinsky D; Cheifetz AS; Korzenik JR
Aliment Pharmacol Ther; 2011 Dec; 34(11-12):1318-27. PubMed ID: 21957906
[TBL] [Abstract][Full Text] [Related]
11. Evolution of Costs of Inflammatory Bowel Disease over Two Years of Follow-Up.
van der Valk ME; Mangen MJ; Severs M; van der Have M; Dijkstra G; van Bodegraven AA; Fidder HH; de Jong DJ; van der Woude CJ; Romberg-Camps MJ; Clemens CH; Jansen JM; van de Meeberg PC; Mahmmod N; van der Meulen-de Jong AE; Ponsioen CY; Bolwerk C; Vermeijden JR; Siersema PD; Leenders M; Oldenburg B;
PLoS One; 2016; 11(4):e0142481. PubMed ID: 27099937
[TBL] [Abstract][Full Text] [Related]
12. Physicians Should Provide Shared Decision-Making for Anti-TNF Therapy to Inflammatory Bowel Disease Patients.
Cha JM; Park DI; Park SH; Shin JE; Kim WS; Yang SK
J Korean Med Sci; 2017 Jan; 32(1):85-94. PubMed ID: 27914136
[TBL] [Abstract][Full Text] [Related]
13. Practical guidelines for treating inflammatory bowel disease safely with anti-tumour necrosis factor therapy in Australia.
Connell W; Andrews JM; Brown S; Sparrow M
Intern Med J; 2010 Feb; 40(2):139-49. PubMed ID: 20446955
[TBL] [Abstract][Full Text] [Related]
14. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease.
Herrinton LJ; Liu L; Weng X; Lewis JD; Hutfless S; Allison JE
Am J Gastroenterol; 2011 Dec; 106(12):2146-53. PubMed ID: 22031357
[TBL] [Abstract][Full Text] [Related]
15. The effects of race and socioeconomic status on immunomodulator and anti-tumor necrosis factor use among ambulatory patients with inflammatory bowel disease in the United States.
Lin KK; Sewell JL
Am J Gastroenterol; 2013 Dec; 108(12):1824-30. PubMed ID: 24300857
[TBL] [Abstract][Full Text] [Related]
16. Methotrexate for psoriasiform lesions associated with anti-tumour necrosis factor therapy in inflammatory bowel disease.
Buisson A; Cuny JF; Barbaud A; Schmutz JL; Bigard MA; Guéant JL; Peyrin-Biroulet L
Aliment Pharmacol Ther; 2012 May; 35(10):1175-80. PubMed ID: 22469155
[TBL] [Abstract][Full Text] [Related]
17. Incidence of renal cell carcinoma in inflammatory bowel disease patients with and without anti-TNF treatment.
Wauters L; Billiet T; Papamichael K; Ballet V; Joniau S; Verschueren P; Silversmit G; Van Assche G; Vermeire S; Ferrante M
Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):84-90. PubMed ID: 27603297
[TBL] [Abstract][Full Text] [Related]
18. Genetic associations with adverse events from anti-tumor necrosis factor therapy in inflammatory bowel disease patients.
Lew D; Yoon SM; Yan X; Robbins L; Haritunians T; Liu Z; Li D; McGovern DP
World J Gastroenterol; 2017 Oct; 23(40):7265-7273. PubMed ID: 29142473
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcome of a third anti-TNF monoclonal antibody after the failure of two prior anti-TNFs in inflammatory bowel disease.
de Silva PS; Nguyen DD; Sauk J; Korzenik J; Yajnik V; Ananthakrishnan AN
Aliment Pharmacol Ther; 2012 Sep; 36(5):459-66. PubMed ID: 22784296
[TBL] [Abstract][Full Text] [Related]
20. May you never forget what is worth remembering: the relation between recall of medical information and medication adherence in patients with inflammatory bowel disease.
Linn AJ; van Dijk L; Smit EG; Jansen J; van Weert JC
J Crohns Colitis; 2013 Dec; 7(11):e543-50. PubMed ID: 23660489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
